An international expert panel, convened by Breakthrough T1D and endorsed by 20 global diabetes organizations, has published a landmark consensus in Diabetologia calling for general population screening for type 1 diabetes (T1D). The guidance recommends testing children for islet autoantibodies (IAbs) at ages 2–4, 6–8, and 10–15 — a major shift from the current practice of screening only family members or those with known genetic risk. The rationale is clear: roughly 85–90% of people who develop T1D have no family history, meaning targeted screening alone misses the vast majority of cases.

The consensus emphasizes that infrastructure must come before screening — countries need systems in place to confirm positive results, monitor early-stage patients, and provide psychosocial support before launching broad programs. Spain has proposed a structured care pathway along similar lines, and Italy's existing program has demonstrated a meaningful reduction in diabetic ketoacidosis (DKA) at diagnosis. Not everyone is aligned yet: the ADA currently recommends only targeted screening, and the AAP has not issued formal guidance.

Key Takeaways:

• Screen children at ages 2–4, 6–8, and 10–15; a one-time screen can be considered for those over 15
• T1D is staged 0–3 based on autoantibody count and glucose levels; early detection enables access to therapies like teplizumab (Tzield) to delay disease onset
• Infrastructure first: confirmatory testing, monitoring pathways, and psychosocial support must be in place before broad screening begins
• False positives, anxiety, and stigma are identified harms — mitigated through education, confirmatory testing, and behavioral health referrals

Why it matters: Early T1D detection can prevent life-threatening DKA at diagnosis, open doors to disease-modifying therapies, and potentially delay full insulin dependence — but only if healthcare systems build the infrastructure to act on what screening reveals.